학술논문
Myelodysplastic clones arising post chimeric antigen receptor t cell therapy (car-t) procedure: a casuality or a new entity?
Document Type
Article
Author
Source
Subject
*CHIMERIC antigen receptors
*STEM cell transplantation
*CELLULAR therapy
*NUCLEOTIDE sequencing
*
*
*
Language
ISSN
0939-5555
Abstract
From January 2021, 2 months after CAR-T treatment, the blood cell count revealed several episodes of cyclic neutropenia without consequences that did not need specific treatment. Dear Editor, CD19-targeted chimeric antigen receptor-modified T-cell (CAR-T cell) immunotherapy has shown excellent anti-tumor activity in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) [[1]] and non-Hodgkin lymphoma (NHL) [[2]], which led to the approval of tisagenlecleucel and axicabtagene ciloleucel by the USA Food and Drug Administration (FDA). [Extracted from the article]